Capital Advisors Ltd. LLC Increases Position in Danaher Co. (NYSE:DHR)

Capital Advisors Ltd. LLC raised its position in Danaher Co. (NYSE:DHR) by 2.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,888 shares of the conglomerate’s stock after purchasing an additional 44 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Danaher were worth $471,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Danaher during the fourth quarter worth $1,752,382,000. Wellington Management Group LLP increased its position in shares of Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after acquiring an additional 3,905,449 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Danaher by 214.4% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after acquiring an additional 2,096,038 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares during the period. Finally, Capital International Investors increased its position in shares of Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $240.41 on Wednesday. The business has a fifty day moving average of $256.13 and a two-hundred day moving average of $246.86. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company has a market cap of $178.07 billion, a P/E ratio of 40.75, a price-to-earnings-growth ratio of 3.82 and a beta of 0.84. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the business posted $2.36 earnings per share. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Citigroup increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. TD Cowen upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird upped their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Finally, Barclays upped their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.67.

Insider Buying and Selling at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock valued at $37,536,717 over the last quarter. Corporate insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.